2024
Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure
Oddleifson D, Holmes D, Alhanti B, Xu X, Heidenreich P, Wadhera R, Allen L, Greene S, Fonarow G, Spatz E, Desai N. Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure. JAMA Cardiology 2024, 9: 222-232. PMID: 38170516, PMCID: PMC10765313, DOI: 10.1001/jamacardio.2023.5009.Peer-Reviewed Original ResearchNon-BPCI hospitalsCause readmission rateReadmission ratesHeart failureSignificant differential changesCare measuresHospital participationBPCI hospitalsHospital mortalityEnzyme inhibitors/angiotensin receptor blockersMortality rateBPCI programAngiotensin receptor neprilysin inhibitorEvidence-based β-blockersGuidelines-Heart Failure registryEnd pointBPCI Model 2Heart failure educationAngiotensin receptor blockersPrimary end pointSecondary end pointsThird of patientsCardiac resynchronization therapyCause mortality ratesHeart failure program
2022
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication prices